GSK Share: Strong H1, Weak Price – Down 16% but Still 68% Undervalued
GlaxoSmithKline, widely known as GSK, recently reported a robust first half of 2025, with strong performance in its specialty medicines division and a bold forecast upgrade. Yet, paradoxically, the GSK share price remains weak, down around 16% from its year-high, despite evidence pointing to deep undervaluation. Solid H1 Performance but Price Lags GSK delivered a…